Skip to main content
. Author manuscript; available in PMC: 2010 Jun 28.
Published in final edited form as: Cell Cycle. 2009 Jun 20;8(12):1940–1951. doi: 10.4161/cc.8.12.8798

Figure 2. Effects of PI-083 and Bortezomib on proteasomal CT-L activities in cancer and normal/immortalized cells.

Figure 2

Exponentially growing cancer cells (■) and normal cells (□) were treated with indicated concentrations of PI-083 (left panel) or Bortezomib (right panel) for 24 h, followed by measurement of CT-L activity in whole cell extracts. (A) MCF-7 breast cancer and MCF-10A breast epithelial cells. (B) T80-Hras ovarian cancer and T80 ovarian epithelial cells. (C) HPDE6-C7-Kras pancreatic cancer and HPDE6-C7 pancreatic epithelial cells. The graphs represent the means ± standard deviation of at least 3 independent experiments. Asterisks indicate statistical significance (p < 0.05).